Cargando…

The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity

Glucose-dependent insulinotropic polypeptide (GIP) (also known as gastric inhibitory polypeptide) is a hormone produced in the upper gut and secreted to the circulation in response to the ingestion of foods, especially fatty foods. Growing evidence supports the physiological and pharmacological rele...

Descripción completa

Detalles Bibliográficos
Autor principal:	Fukuda, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	Diabetes Symposium
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576424/ https://www.ncbi.nlm.nih.gov/pubmed/34176784 http://dx.doi.org/10.2337/dbi21-0001

Ejemplares similares

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
por: Ludwig, Mette Q., et al.
Publicado: (2021)

GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Basedz Therapies in Treating Metabolic Disorders
por: Samms, Ricardo J., et al.
Publicado: (2021)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

A Primary Role for α-Cells as Amino Acid Sensors
por: Dean, E. Danielle
Publicado: (2020)

The TCF7L2 Locus: A Genetic Window Into the Pathogenesis of Type 1 and Type 2 Diabetes
por: Grant, Struan F.A.
Publicado: (2019)

Cerebrospinal fluid PCR: A new approach for the diagnosis of CNS sporotrichosis
por: Oliveira, Manoel Marques Evangelista, et al.
Publicado: (2020)

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
por: Hartman, Mark L., et al.
Publicado: (2020)

Vaccination against GIP for the Treatment of Obesity
por: Fulurija, Alma, et al.
Publicado: (2008)

Defining Heterogeneity Among Women With Gestational Diabetes Mellitus
por: Powe, Camille E., et al.
Publicado: (2020)

Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment
por: Dennis, John M.
Publicado: (2020)

The Local Paracrine Actions of the Pancreatic α-Cell
por: Rodriguez-Diaz, Rayner, et al.
Publicado: (2020)

Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
por: Finan, Brian, et al.
Publicado: (2020)

The Liver–α-Cell Axis in Health and in Disease
por: Richter, Michael M., et al.
Publicado: (2022)

Hypothalamic Inflammation: Marker or Mechanism of Obesity Pathogenesis?
por: Thaler, Joshua P., et al.
Publicado: (2013)

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
por: Sparre‐Ulrich, A H, et al.
Publicado: (2015)

Physiological roles of the GIP receptor in murine brown adipose tissue
por: Beaudry, Jacqueline L., et al.
Publicado: (2019)

Toward a More Complete (and Less Controversial) Understanding of Energy Expenditure and Its Role in Obesity Pathogenesis
por: Kaiyala, Karl J., et al.
Publicado: (2011)

Pathogenesis of prostate cancer and hormone refractory prostate cancer
por: Girling, J. S., et al.
Publicado: (2007)

Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial
por: Helsted, Mads M, et al.
Publicado: (2023)

Infraorbital Dark Circles: A Review of the Pathogenesis, Evaluation and Treatment
por: Vrcek, Ivan, et al.
Publicado: (2016)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Marked Cortisol Production by Intracrine ACTH in GIP-Treated Cultured Adrenal Cells in Which the GIP Receptor Was Exogenously Introduced
por: Fujii, Hiroko, et al.
Publicado: (2014)

Epigenetics of the Pathogenesis and Complications of Type 2 Diabetes Mellitus
por: Mannar, Velmurugan, et al.
Publicado: (2023)

Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease
por: Yarchoan, Mark, et al.
Publicado: (2014)

Insulin Action in Brain Regulates Systemic Metabolism and Brain Function
por: Kleinridders, André, et al.
Publicado: (2014)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
por: Zhang, Qian, et al.
Publicado: (2021)

GIP1 and GIP2 Contribute to the Maintenance of Genome Stability at the Nuclear Periphery
por: Singh, Gaurav, et al.
Publicado: (2022)

Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: An association analysis of polymorphisms and bone in young and elderly women
por: Garg, Gaurav, et al.
Publicado: (2015)

Absence of GIP secretion alleviates age-related obesity and insulin resistance
por: Kanemaru, Yoshinori, et al.
Publicado: (2020)

The molecular pathogenesis of dedifferentiated chondrosarcoma
por: Sakamoto, Akio
Publicado: (2014)

Human African Trypanosomiasis Presenting at Least 29 Years after Infection—What Can This Teach Us about the Pathogenesis and Control of This Neglected Tropical Disease?
por: Sudarshi, Darshan, et al.
Publicado: (2014)

Handling difficult anastomosis. Tips and tricks in obese patients and narrow pelvis
por: Samavedi, Srinivas, et al.
Publicado: (2014)

GIP receptor agonism blocks chemotherapy-induced nausea and vomiting
por: Borner, Tito, et al.
Publicado: (2023)

Current Understanding in Pathogenesis of Atopic Dermatitis
por: McPherson, Tess
Publicado: (2016)

Mechanism of Cancer Growth Suppression of Alpha-Fetoprotein Derived Growth Inhibitory Peptides (GIP): Comparison of GIP-34 versus GIP-8 (AFPep). Updates and Prospects
por: Mizejewski, Gerald J.
Publicado: (2011)

Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas
por: Kovatchev, Boris P., et al.
Publicado: (2014)

Feasibility of Outpatient Fully Integrated Closed-Loop Control: First studies of wearable artificial pancreas
por: Kovatchev, Boris P., et al.
Publicado: (2013)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_75ug7g6uio7of03rtoun1eqibb